

The problem: Antimicrobial resistance


- Urinary tract infection (UTI) is the **most common bacterial infection** in humans
- 450M UTI episodes every year worldwide, whereof **> 50M in Europe and the US**
- 40-60% of UTI episodes **lack diagnostics or are misdiagnosed** – exceeding 80% in many LMIC
- Misdiagnosis **delays effective antimicrobial treatment and cause unnecessary use of antibiotics**, increasing the risk of complications, and driving antibiotic resistance
- **Established POCT tests** offer **limited performance**, and **lack bacteria ID and AST**

The solution: Utilizer-ID and Utilizer ID+AST

- Utilizer is an **instrument-free dipstick test** with **colour-based read-out** to reveal bacteria identification (ID), quantification and antimicrobial susceptibility (AST)
- **Mobile phone imaging** with automated software analysis and result read-out
- Same-day **5 hours time to result** for bacteria ID, directly from urine, with flexible read-out time
- Utilizer-ID is in production with **medical device CMOs**, Utilizer-ID+AST is in development
- Target COGS **< EUR 3/test**

Utilizer technology and USPs

Step-by step process



Utilizer technology:


- Optimised media enables bacteria identification (ID) through a clear **colour read-out**
- **Miniaturised dipstick wells** enable standardised bacterial quantification and shortened time to result
- **Digital read-out** supports objective interpretation, reduces human error and facilitates integration with laboratory information system (LIS)

Unique selling points:

1. One-of-a-kind instrument-free UTI diagnostics – in a single dipstick
2. Flexible read-out time for easy work-flow integration
3. Reimbursed, reliable results in near-patient care
4. Scalable business model with cost-efficient manufacturing



Bacteria quantification: 10^3 - 10^5 CFU/mL



Bacteria identification:

E. coli, *K. pneumoniae*, *P. mirabilis*,
E. faecalis, *S. saprophyticus* etc.
– covering >97% of UTI pathogens

Performance evidence

Clinical evaluation at Karolinska University Hospital:

- 104 clinical urine samples
- Comparison with standard urine culture and MALDI
- Clinical evaluation confirms that **Utilizer-ID delivers rapid results directly from urine, consistent with clinical microbiology laboratory testing**

Utilizer-ID	Sensitivity	Specificity
Bacteria detection	100%	100%
Bacteria identification	99%	97%
High sensitivity and specificity support reliable UTI pathogen detection, few missed infections and more targeted treatment		

Commercial opportunity

Veterinary market
Utilizer-ID
Utilizer-ID+AST

EUR 50m addressable veterinary market in **Europe** – tests for companion animals

Market: 3M tests/yr

launch 2027

IVD market
Utilizer-ID
Utilizer-ID+AST

EUR 300m addressable IVD market in **Europe and US**

Market: 22M tests/yr

launch 2029

Food control
Utilizer-ID

Rapid detection and identification of pathogens in food, dairy and industrial hygiene products

FOOD SAFETY

Bioburden market
Utilizer-ID

Rapid detection, quantification and identification of pathogens in respiratory systems etc.

LMIC opportunity: High UTI burden and antimicrobial resistance

High UTI burden and limited access to microbiology diagnostics in South Asia and sub-Saharan Africa create a strong need for affordable rapid testing. WHO prequalification, if applicable, facilitates procurement of tests by UN agencies and other global health partners.



Go to market roadmap

2027

Launch of **Utilizer-ID** with SLU University Animal Hospital (veterinary market)

2027

Achieve **ISO 13485** certification & advance **Utilizer-ID+AST** product readiness

2028


Complete European **IVD performance evaluation studies**

2028

Secure **commercial partnerships** for market expansion & scale-up

2028/2029

Achieve **CE-IVDR** certification and **launch in Europe** (human market)



Completed and on-going clinical evaluations:

- 1,200+ urine samples across near-patient care, veterinary hospitals and clinical microbiology laboratories
- Clinical sites include for example **Karolinska University Hospital** and **primary care sites** (Sweden), **SLU University Animal Hospital** (Sweden) and **Makerere University Hospital** (Uganda) and **HealthClinics**

Management team and advisors

Management team

Dr Sofia Bertling
CEO and co-founder
Medtech and commercial leader, former Hermes medical and Sectra

Gabriella von Flittner
Director sales & marketing
Experienced IVD commercial leader, former VP Aidian

Dr Emre Iseri
CTO and co-founder
Research in microfluidics, digital testing for infectious diseases

Advisors

Dr Alex van Belkum
R&D advisor
Renowned microbiologist, former VP R&D bioMérieux

Juho Himberg
Board member
Medtech executive, former e.g. CEO Aidian, VP Gambro

Dr Patrick Griss
Executive advisor
Tech & Business Advisor Prior Roche Innovations, CEO Zulke Ventures

Use of proceeds

- Use of proceeds EUR 4M will be for:
- Veterinary market entry
 - Development Utilizer-ID+AST
 - Manufacturing extensions
 - ISO 13485 and CE-IVDR regulatory process
 - IVD market access preparation